ClinicalTrials.gg
Status unknownNCT04574817Updated Oct 5, 2020

Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)

A Phase 2 interventional study of HX008 in Anaplastic Thyroid Cancer, sponsored by Taizhou Hanzhong biomedical co. LTD. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-05.

Sponsored by Taizhou Hanzhong biomedical co. LTD · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

There are currently no target therapies approved for treatment of anaplastic thyroid cancer (ATC), leading to a clear need for improving therapy for ATC. This is a single-arm, multicenter study to evaluate the efficacy and safety of HX008 injection in patients with metastatic or locally advanced anaplastic thyroid cancer.

02

Conditions studied

  • Anaplastic Thyroid Cancer
03

In context

Thyroid Carcinoma, Anaplastic

87 studies on the registry are indexed under Thyroid Carcinoma, Anaplastic; 18 are open to participants now.

This study's planned enrollment of 66 is above the median of 30 across 71 interventional studies indexed under Thyroid Carcinoma, Anaplastic.

Browse Thyroid Carcinoma, Anaplastic studies →

Lead sponsor

Taizhou Hanzhong biomedical co. LTD is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be willing and able to provide written for the trial.
  • Age ≥ 18 years old, male or female.
  • Subjects must have histological diagnosis of inoperative IVB or IVC stage anaplastic thyroid cancer.
  • Prior , adjuvant or palliative chemotherapy for ATC is allowed, there is no limit to the number of a patient has received.
  • Have based on 1.1.
  • Willing to provide tissue for biomarker analysis.
  • Has a performance status of 0 or 1 on the (ECOG) Performance Score.
  • ≥ 3 months.
  • Has adequate organ function as defined in the protocol.
  • Female subject of should have a negative serum pregnancy within 72 hours prior to receiving the first dose of study treatment.
  • Male and female participants should agree to use an adequate method of during the experiment and 6 months after the last administration of the test drugs.

Exclusion criteria

Exclusion Criteria:

  • Subjects who are suitable or intent to receive local treatment.
  • Differentiated thyroid cancer (DTC) or medullary thyroid cancer (MTC). ATC arising out of DTC is allowed, as long as the is clinically consistent with ATC i.e., rapidly progressive and/or 18F fluorodeoxyglucose (FDG)-avid.
  • Subjects diagnosed with any other within 3 years prior to the first dose of HX008, except for malignancies with a low risk of and death (5-year survival rate > 90%), such as basal cell or squamous cell skin cancer or carcinoma in situ of the cervix and other carcinomas in situ.
  • Has had a prior anti-cancer monoclonal antibody within 4 weeks prior to the first dose of trial treatment or who has not recovered (≤ Grade 1 or at Baseline) from AEs due to agents administered more than 4 weeks earlier.
  • Has had prior chemotherapy, radiation therapy or targeted small molecular therapy within 2 weeks prior to the first dose of trial treatment or who has not recovered (≤ Grade 1 or at Baseline) from AEs due to a previously administrated agent.
  • Has had prior herbal medicine within 1 week prior to the first dose of trial treatment.
  • Has received prior therapy with an , or anti-PD-L1, or anti-CTLA-4 agents.
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Has active disease that has required systemic treatment in past 2 years.
  • Has received a major surgery within 4 weeks prior to the first dose of trial treatment.
  • Has received system treatment with (dose >10mg/day prednison or other therapeutic hormones) within 2 weeks prior to the first dose of trial treatment.
  • Has a history of interstitial lung disease.
  • Has uncontrolled cardiovascular disease, including but not limited to: 1) heart failure greater than (NYHA) class II; 2) unstable angina pectoris; 3) has myocardial infarction within 1 year; 4) supraventricular or ventricular arrhythmias with clinical significance.
  • Has uncontrolled systemic disease, such as diabetes or hypertension.
  • Has a history of active tuberculosis.
  • Has a history of testing positive for (HIV), or known acquired immunodeficiency syndrome (AIDS), or stem cell transplantation or organ transplantation.
  • Has uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  • Has untreated chronic or chronic hepatitis B virus (HBV) DNA exceeding 500 IU/ mL or active virus (HCV). Subjects with non-active HBsAg carriers, treated and stable hepatitis B (HBV DNA \< 10\^3 copies/ml or \<500 IU/ mL) , and cured hepatitis C can be enrolled. Subjects with positive HCV antibodies are eligible only if the HCV RNA test results are negative.
  • Has a history of severe allergic reaction to any other monoclonal antibodies.
  • Has active infections requiring systemic treatment within 2 weeks prior to the first dose of trial treatment.
  • Has participated in other anticancer drug clinical trials within 4 weeks.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial.
  • Has received a within 30 days prior to the first dose of trial treatment.
  • According to the judgement of the investigators, there are other factors that may lead to the termination of the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    HX008

    Participants will receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W)

    Drug: HX008

Interventions

  • DrugHX008

    200 mg administered as IV infusion on Day 1 of each 21-day cycle.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Percentage of subjects achieving complete response (CR) and partial response (PR)

    Time frame: Up to approximately 30 months

Secondary outcomes

  1. Disease Control Rate (DCR)

    DCR was defined as the percentage of participants who have a CR or a PR or a stable disease (SD)

    Time frame: Up to approximately 30 months

  2. Duration of Response (DOR)

    DOR was defined as the time from the first documented evidence of a response of CR or PR to the first documented disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 30 months

  3. Progression-free Survival (PFS)

    PFS was defined as the time from the date of beginning of HX008 administration to the first documented disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 30 months

  4. Overall Survival (OS)

    OS was defined as the time from the date of beginning of HX008 administration until date of death from any cause.

    Time frame: Up to approximately 30 months

  5. Adverse Effect (AE)

    Adverse events associated with HX008

    Time frame: Up to approximately 30 months

07

Study locations

1 site
  • Cancer Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2020; primary completion for May 2022, 17 months later.

Of 25 phase 2 interventional studies under Thyroid Carcinoma, Anaplastic, half reached primary completion within 92 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 112. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2020
First posted
Oct 5, 2020
StartEst.
Dec 28, 2020
Primary completionEst.
May 30, 2022
CompletionEst.
May 30, 2023
Last update
Oct 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04574817
Lead sponsor
Taizhou Hanzhong biomedical co. LTD
Responsible party
Sponsor
First posted
Oct 5, 2020
Start date
Dec 28, 2020 (estimated)
Primary completion
May 30, 2022 (estimated)
Completion
May 30, 2023 (estimated)
Last update
Oct 5, 2020

Study contacts

Yuankai Shi
Contact
syuankai@cicams.ac.cn
010-87788293

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pucotenlimab

Start the discussion